Background: We sought to determine the prognostic value of pathologic response to neoadjuvant chemotherapy with concurrent trastuzumab.
delivered in the neoadjuvant setting has been evaluated. In the first randomized trial to evaluate the addition of trastuzumab to chemotherapy in the neoadjuvant setting, Buzdar et al. [11] reported a 66.7% pCR rate among patients receiving chemotherapy plus trastuzumab versus 25% among patients receiving chemotherapy alone (P = 0.02). After this, the GeparQuattro [12] and NOAH [13] (NeOAdjuvant Herceptin) trials have shown improved pCR rates among patients receiving trastuzumab, with an event-free survival benefit seen at 3 years among patients treated with trastuzumab in the NOAH trial. Long-term clinical outcomes as a function of achieving a pCR have not been reported from these studies.
In this study, we evaluated the prognostic value of achieving a pCR following neoadjuvant chemotherapy with trastuzumab. Locoregional recurrence-free, distant metastasis-free (DMFS), recurrence-free (RFS), and overall survival (OS) outcomes were evaluated to characterize the long-term benefit of a pCR.
materials and methods patient population and treatment
Patients with non-metastatic, non-inflammatory HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy plus trastuzumab between 2001 and 2008 were identified. HER2-overexpressing disease was defined as 3+ on immunohistochemistry or gene amplification on fluorescence in situ hybridization. HER2 status was confirmed by a dedicated breast pathologist. Patients received a variety of neoadjuvant regimens (Table 1) . Following the completion of neoadjuvant chemotherapy, all patients underwent surgery; either total mastectomy with axillary lymph node evaluation or BCT (segmental mastectomy, axillary node evaluation, and whole breast irradiation). After a favorable clinical response to neoadjuvant therapy, most of the patients were offered BCT. Mastectomy was carried out according to patient preference, diffuse residual calcifications, or when clinical response assessment inaccurately predicted more extensive residual disease. Excised specimens were routinely subjected to intraoperative assessment. Specimens were oriented, marked, and sectioned into 3-to 5-mm sections examined grossly by a pathologist, and then subjected to specimen radiograph. If these evaluations suggested a close margin, re-excision was carried out at the initial operation. All patients undergoing BCT received external-beam whole-breast irradiation with tangential fields. Regional nodal radiation in the case of BCT or postmastectomy radiation for patients undergoing mastectomy was generally recommended for patients presenting with clinical stage III disease and for those with residual positive lymph nodes identified pathologically. Adjuvant endocrine therapy was generally administered for hormone receptor-positive disease.
end points and statistical methods
A pCR was defined as no residual invasive disease in the breast or axillary lymph nodes, regardless of non-invasive disease status. For additional comparison, patients were categorized by the extent of remaining disease according to pathologic stage as defined by the 7th edition of the American Joint Committee on Cancer staging system.
Locoregional recurrence was defined as any relapse within the breast or ipsilateral chest wall, and/or ipsilateral axillary, internal mammary, infraclavicular, or supraclavicular nodal regions, regardless of systemic disease status. Distant relapse included all non-locoregional recurrences and was determined independent of locoregional disease status. All survival outcomes were calculated from the date of diagnosis to the date of relapse, date when the patient was last known to be relapse free, or death.
Statistical analysis was carried out using SPSS (SPSS, Inc., Chicago, IL) and Stata (StataCorp LP, College Station, TX). The chi-square statistic was used to evaluate differences in prognostic factors between groups. KaplanMeier analysis was used to calculate survival outcomes and subgroups compared using log-rank statistic. Cox proportional hazards regression was used to estimate relapse and survival risk between subgroups. Covariates used in the model included estrogen and/or progesterone receptor (ER/PR) status, age, menopausal status, T-stage, N-stage, stage group, grade, presence of lymphovascular invasion (LVI), surgery type, radiation therapy, surgical margin status, treatment with hormone therapy, pathologic response to neoadjuvant therapy, and length of trastuzumab treatment. The proportional hazards assumption was tested and upheld. All tests were two-sided with an alpha = 0.05. This study was approved by the MD Anderson Institutional Review Board.
results patient characteristics and clinical outcomes
A pCR was achieved in 114 (49.8%) patients. Disease and treatment characteristics according to pathologic response are Trastuzumab given as a 4-mg/kg loading dose, followed by 2 mg/kg weekly during the 24 weeks of chemotherapy. original articles Annals of Oncology listed in Table 2 . The median follow-up was 63 (interquartile range, 53-77) months. None of the patients achieving a pCR had a locoregional failure. Locoregional failures occurred in six patients with less than a pCR ( Figure 1A ), DMFS was higher among patients achieving a pCR compared with less than a pCR (5-year DMFS, 96% versus 80%, P < 0.001, Figure 1B) . Five-year RFS (96% versus 79%, P < 0.001) and OS (95% versus 84%, P = 0.006) rates were also significantly higher among patients achieving a pCR ( Figure 1C and D) .
To determine the significance of residual ductal carcinoma in situ (DCIS), patients categorized as a pCR with residual DCIS were identified (n = 35) and compared with those that had no residual invasive disease or DCIS in the breast and axillary lymph nodes (n = 79). No locoregional failures were seen in either group. At 5 years, DMFS was 95% versus 97% (P = 0.428), and OS was 96% versus 94% (P = 0.655) for those with no residual invasive disease or DCIS versus those with residual DCIS.
Following neoadjuvant therapy, 54 (23%) patients had pathologic stage I disease, 40 (18%) stage II, and 21 (9%) stage III disease. Survival outcomes were inversely correlated with increasing burden of remaining disease (Figure 2A-D) .
Cox regression analysis for factors associated with distant relapse
The most significant predictor for distant metastasis on multivariate analysis was failure to achieve a pCR (adjusted hazard ration [HR] 3.75, 95% confidence interval [CI] 1.52-9.26, P = 0.004). Patients with clinical T3-4 compared with T1-2 disease, and patients with LVI, were more likely to have systemic relapse (adjusted HR 2.61, 95% CI 1.27-5.39, P = 0.009 and adjusted HR 2.13, 95% CI 1.02-4.46, P = 0.045, respectively). Assessment for interaction between pCR and ER/ PR status on distant metastasis risk was not significant (P = 0.099). Whether trastuzumab was given for a full-year or less did not influence distant metastasis risk (HR 0.88, 95% CI 0.43-1.82, P = 0.727).
Cox regression analysis for recurrence-free and overall survival
Predictors of RFS and OS are listed in Table 3 . Of evaluated factors, failure to achieve a pCR was the strongest predictor of disease recurrence and death. To a lesser degree, advanced clinical T-stage (T3-4) increased the hazard of recurrence and death compared with patients with stage T1-2 tumors, after controlling for other factors. LVI was a significant predictor of disease recurrence. No interaction was seen between ER/PR status and pCR on RFS and OS (P = 0.103 and 0.147, respectively).
Among pathologic stage groups, an increased risk of recurrence and death was seen among patients with increasing pathologic stage (Table 4) . Compared with patients achieving a pCR, patients with pathologic stage II or III disease had a significantly higher risk of recurrence and death. No interaction between pCR and locoregional treatment on recurrence and survival outcomes was seen.
discussion
The addition of trastuzumab to anthracycline and taxane-based chemotherapy in the neoadjuvant setting among women with HER2-positive breast cancer has resulted in pCR rates ranging from 32% to 66% and improvements in event-free survival Annals of Oncology original articles [11] [12] [13] [14] . In this study, we report the long-term benefit of achieving a pCR. Specifically, pCR was a significant predictor of DMFS, RFS, and OS. Moreover, an increased risk of recurrence and death was seen among patients with increasing burden of remaining disease after neoadjuvant therapy. After controlling for disease-and treatment-related factors, achieving a pCR was the strongest predictor of long-term outcome.
Our results are consistent with data from the TECHNO trial, a phase II non-randomized study [15] of 217 patients with HER2-overexpressing disease who received 6 months of neoadjuvant epirubicin and paclitaxel-based (Bristol-Myers Squibb, New York) chemotherapy and trastuzumab. In this trial, pCR was achieved in 39%. Disease-free and OS outcomes were superior among patients achieving a pCR compared with those with less than pCR, and pCR was the strongest prognostic factor for relapse and death. Locoregional and distant patterns of relapse were not described in that study. Similarly, in our study, we found that achieving a pCR was the strongest predictor of long-term disease control and survival, even after controlling for various disease and treatment-related factors. In addition, locoregional and distant relapse rates were encouragingly low after a median follow-up of 5 years.
Our study highlights the complex interplay between tumor biology, treatment response, and long-term clinical outcome.
In our series, neoadjuvant trastuzumab-containing chemotherapy was effective in eradicating invasive disease in nearly 50% of patients and in our multivariate model, pCR retained a strong association with survival, even after controlling for standard clinical and pathologic prognostic factors. For patients not achieving a pCR, we found an inverse relationship between residual disease, as indicated by pathologic stage, and long-term disease control and survival. In the subset of patients with residual DCIS after neoadjuvant therapy, no differences in distant metastasis and OS outcomes were noted compared with those achieving eradication of invasive and non-invasive disease in the breast and axilla. This is consistent with a recent meta-analysis of 12 randomized neoadjuvant chemotherapy trials [16] . This analysis found that 13% of patients had a pCR defined as no residual invasive disease in the breast or axilla and 18% had a pCR defined as no residual invasive or in situ disease in the breast. A pCR by either definition predicted for improved event-free survival and OS. These data and our results are in contrast to a study by von Minckwitz et al. [17] that evaluated over 6000 patients enrolled on seven prospective trials of neoadjuvant chemotherapy and showed that patients with residual DCIS in the breast did worse with respect to disease-free survival and trended towards worse OS. In subset analyses evaluating 622 Figure 1 . Kaplan-Meier curves of (A) locoregional recurrence-free, (B) distant metastasis-free, (C) recurrence-free, and (D) overall survival outcomes among patients achieving a pathologic complete response ( pCR) versus less than a pCR.
original articles
Annals of Oncology patients with HER2-positive disease that received trastuzumab as part of their neoadjuvant chemotherapy, a pCR defined as no residual invasive disease or DCIS in the breast and axillary lymph nodes was associated with improved disease-free and OS [18] . Although a higher percentage of patients with hormone receptor-negative tumors in our study achieved a 
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pCR than those with hormone receptor-positive disease as seen in other studies [5, 19, 20] , no interaction between hormone receptor status and pCR on distant metastasis, disease relapse, or OS was seen, highlighting the prognostic significance of pCR on long-term outcome independent of hormone receptor status. In addition, whether trastuzumab was delivered in the neoadjuvant setting alone or continued for 1 year did not impact relapse and survival outcomes in our study. Limitations of this study include its retrospective design that did not permit the assessment of independent causality between pathologic response and outcome. Among the strengths of this study include specialized pathology review of all cases, consistent multidisciplinary care and median followup greater than 5 years during which most of the recurrences have been shown to occur in patients with HER2-overexpressing breast cancer.
In conclusion, achievement of pCR among patients with HER2-overexpressing breast cancer was the strongest predictor of disease control and survival. Given recent success of combined HER2-directed therapies in the neoadjuvant setting achieving even higher pCR rates [21] , a greater benefit on long-term outcome would be predicted with this strategy. These findings underscore the potential value of pathologic response as an early surrogate of long-term outcome, and an important metric for future studies evaluating new HER2-targeted therapies. Consistent with this, the Food and Drug Administration has proposed [22] using pCR as a surrogate end point, allowing for accelerated approval of therapeutics. Such an approach would allow for the most promising investigational drugs to be rapidly incorporated into treatment algorithms maximizing benefit for breast cancer patients with high-risk disease. 
